Table 1.

Patient characteristics

Pt. No.	Age (y), Gender	Eye	Clinical presentation	VA	Treatment modality	Radiation dose (dose @ isodose × fractions)	Optic nerve isodose (range)	Retinal isodose (range)	Visual outcome	Radiologic outcome	Toxicity	Follow-up (mo)
1	46, F	Right	VA loss	Finger counting at 3 ft.	FCRT	6 Gy @ 80% × 6 = 36 Gy	40–95%	10–20%	4/200, improved visual field and VA	Tumor regression	Eyelid edema	151
2	47, F	Left	Visual field loss, diminished color vision	20/20	FCRT	1.8 Gy × 30 = 54 Gy (isodose NA)	NA	NA	Improved visual field	Stable	None	132
3	39, M	Left	Visual field loss	20/20	FCRT	1.8 Gy @ 90% × 30 = 54 Gy	90% (1.90–2.01 Gy)	50%	Improved visual field	Stable	Radiation-induced retinopathy	121
4	44, F	Right	Right blindness, orbital pain, headache, proptosis	—	FCRT	1.8 Gy @ 90% × 30 = 54 Gy	95–100% (1.90–2.0 Gy)	NA	Stable visual examination findings	Stable	None	107
5	59, F	Left	Visual field and VA loss	20/300	FCRT	1.8 Gy @ 98% × 30 = 54 Gy	98% (1.81–1.84 Gy)	98% (0.04–1.81 Gy)	20/40, improved visual field and VA	Stable	None	90
6	45, M	Left	Visual loss	20/200	FCRT	1.8 Gy × 30 = 54 Gy (isodose NA)	NA	NA	Improved	Stable	None	78
7	45, M	Left	Visual field loss	20/20	FCRT	1.8 Gy @ 90% × 30 = 54 Gy	90%	98%	Improved visual field	Stable	None	80
8	44, F	Left	Visual loss	20/40	FCRT	1.8 Gy @ 98% × 28 = 50.4 Gy	98% (1.83–1.85 Gy)	72–98% (1.34–1.82 Gy)	Stable	Stable	None	62
9	46, F	Right	Visual field and VA loss	20/30	FCRT	1.8 Gy @ 90% × 28 = 50.4 Gy	90% (1.58–2.10 Gy)	40% (0.08–1.36 Gy)	20/25, improved visual field and VA	Tumor regression	None	61

Abbreviations: Pt. No. = patient number; VA = visual acuity; FCRT = functional conformal radiotherapy; NA = not available.